ULTRAGENYX PHARMACEUTICAL INC. (RARE) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
39/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinRARE / S&P 59.38% / 15.20% |
WinRARE / S&P 17.55% / 15.00% |
LoseRARE / S&P 5.62% / 50.40% |
| 2026-Q11/3 |
LoseRARE / S&P -8.91% / -4.33% |
WinRARE / S&P 13.56% / 11.30% |
LoseRARE / S&P 3.92% / 27.70% |
| 2025-Q41/3 |
LoseRARE / S&P -23.54% / 2.65% |
WinRARE / S&P 20.22% / 9.00% |
LoseRARE / S&P -7.90% / 13.40% |
| 2025-Q31/3 |
LoseRARE / S&P -17.27% / 8.12% |
WinRARE / S&P 20.69% / 4.61% |
LoseRARE / S&P -7.20% / 13.45% |
| 2025-Q21/3 |
LoseRARE / S&P 0.41% / 10.94% |
WinRARE / S&P 26.83% / 4.83% |
LoseRARE / S&P -23.55% / 10.63% |
| 2025-Q11/3 |
LoseRARE / S&P -13.93% / -4.27% |
WinRARE / S&P 33.42% / 4.98% |
LoseRARE / S&P -26.16% / 10.57% |
| 2024-Q41/3 |
LoseRARE / S&P -24.27% / 2.41% |
WinRARE / S&P 29.03% / 5.25% |
LoseRARE / S&P -23.27% / 6.15% |
| 2024-Q32/3 |
WinRARE / S&P 35.16% / 5.89% |
WinRARE / S&P 27.37% / 5.89% |
LoseRARE / S&P -28.76% / 6.11% |
| 2024-Q21/3 |
LoseRARE / S&P -11.97% / 4.28% |
WinRARE / S&P 19.41% / 5.38% |
LoseRARE / S&P -29.49% / 5.12% |
| 2024-Q11/3 |
LoseRARE / S&P -2.36% / 10.56% |
WinRARE / S&P 15.22% / 5.71% |
LoseRARE / S&P -22.44% / 5.59% |
| 2023-Q42/3 |
WinRARE / S&P 34.14% / 11.69% |
WinRARE / S&P 19.45% / 6.81% |
LoseRARE / S&P -18.40% / 7.78% |
| 2023-Q31/3 |
LoseRARE / S&P -22.72% / -3.27% |
WinRARE / S&P 19.46% / 7.52% |
LoseRARE / S&P -7.91% / -5.03% |
| 2023-Q23/3 |
WinRARE / S&P 15.04% / 8.74% |
WinRARE / S&P 20.50% / 9.50% |
WinRARE / S&P 39.89% / -8.57% |
| 2023-Q12/3 |
LoseRARE / S&P -13.45% / 7.50% |
WinRARE / S&P 15.65% / 10.77% |
WinRARE / S&P 49.20% / -15.69% |
| 2022-Q41/3 |
WinRARE / S&P 11.88% / 7.56% |
LoseRARE / S&P 3.39% / 11.88% |
LoseRARE / S&P RARE unavailable / -17.99% |
| 2022-Q30/3 |
LoseRARE / S&P -30.59% / -4.88% |
LoseRARE / S&P -4.50% / 13.47% |
LoseRARE / S&P RARE unavailable / -1.41% |
| 2022-Q20/3 |
LoseRARE / S&P -17.85% / -16.10% |
LoseRARE / S&P -6.98% / 13.71% |
LoseRARE / S&P RARE unavailable / 11.04% |
| 2022-Q10/3 |
LoseRARE / S&P -13.64% / -4.60% |
LoseRARE / S&P -0.65% / 15.97% |
LoseRARE / S&P RARE unavailable / 42.23% |
| 2021-Q41/3 |
LoseRARE / S&P -6.76% / 11.03% |
WinRARE / S&P 29.66% / 15.00% |
LoseRARE / S&P RARE unavailable / 96.40% |
| 2021-Q31/3 |
LoseRARE / S&P -5.41% / 0.58% |
WinRARE / S&P 67.17% / 10.77% |
LoseRARE / S&P RARE unavailable / 69.42% |
| 2021-Q21/3 |
LoseRARE / S&P -16.26% / 8.55% |
WinRARE / S&P 125.44% / 6.58% |
LoseRARE / S&P RARE unavailable / 51.81% |
| 2021-Q11/3 |
LoseRARE / S&P -17.75% / 6.17% |
WinRARE / S&P 174.20% / -1.06% |
LoseRARE / S&P RARE unavailable / 7.39% |
| 2020-Q42/3 |
WinRARE / S&P 68.43% / 12.15% |
WinRARE / S&P 161.32% / -3.72% |
LoseRARE / S&P RARE unavailable / -33.42% |
| 2020-Q31/3 |
LoseRARE / S&P 5.08% / 8.93% |
WinRARE / S&P 154.89% / -2.04% |
LoseRARE / S&P RARE unavailable / -27.10% |
| 2020-Q22/3 |
WinRARE / S&P 76.05% / 20.54% |
WinRARE / S&P 126.61% / -0.46% |
LoseRARE / S&P RARE unavailable / -27.11% |
| 2020-Q12/3 |
WinRARE / S&P 4.03% / -19.60% |
WinRARE / S&P 106.56% / 3.47% |
LoseRARE / S&P RARE unavailable / -14.75% |
| 2019-Q41/3 |
LoseRARE / S&P -0.16% / 9.07% |
WinRARE / S&P 101.41% / 5.36% |
LoseRARE / S&P RARE unavailable / 2.99% |
| 2019-Q31/3 |
LoseRARE / S&P -32.63% / 1.70% |
WinRARE / S&P 124.13% / 5.02% |
LoseRARE / S&P RARE unavailable / 0.21% |
| 2019-Q21/3 |
LoseRARE / S&P -8.45% / 4.30% |
WinRARE / S&P 169.70% / 6.64% |
LoseRARE / S&P RARE unavailable / 8.65% |
| 2019-Q11/3 |
WinRARE / S&P 59.52% / 13.65% |
LoseRARE / S&P RARE unavailable / 8.12% |
LoseRARE / S&P RARE unavailable / 14.29% |
| 2018-Q40/3 |
LoseRARE / S&P -43.04% / -13.52% |
LoseRARE / S&P RARE unavailable / 9.05% |
LoseRARE / S&P RARE unavailable / 18.23% |
| 2018-Q30/3 |
LoseRARE / S&P -0.69% / 7.71% |
LoseRARE / S&P RARE unavailable / 10.21% |
LoseRARE / S&P RARE unavailable / 19.06% |
| 2018-Q21/3 |
WinRARE / S&P 50.76% / 3.43% |
LoseRARE / S&P RARE unavailable / 9.03% |
LoseRARE / S&P RARE unavailable / 14.46% |
| 2018-Q11/3 |
WinRARE / S&P 9.94% / -0.76% |
LoseRARE / S&P RARE unavailable / 7.68% |
LoseRARE / S&P RARE unavailable / 12.46% |
| 2017-Q40/3 |
LoseRARE / S&P -12.92% / 6.64% |
LoseRARE / S&P RARE unavailable / 7.03% |
LoseRARE / S&P RARE unavailable / 13.82% |
| 2017-Q30/3 |
LoseRARE / S&P -14.25% / 4.48% |
LoseRARE / S&P RARE unavailable / 5.68% |
LoseRARE / S&P RARE unavailable / 17.57% |
| 2017-Q20/3 |
LoseRARE / S&P -8.37% / 3.09% |
LoseRARE / S&P RARE unavailable / 4.83% |
LoseRARE / S&P RARE unavailable / 17.74% |
| 2017-Q10/3 |
LoseRARE / S&P -3.60% / 6.07% |
LoseRARE / S&P RARE unavailable / 3.67% |
LoseRARE / S&P RARE unavailable / 13.32% |
| 2016-Q40/3 |
LoseRARE / S&P -0.89% / 3.82% |
LoseRARE / S&P RARE unavailable / 2.09% |
LoseRARE / S&P RARE unavailable / 7.05% |
| 2016-Q31/3 |
WinRARE / S&P 45.04% / 3.85% |
LoseRARE / S&P RARE unavailable / 0.20% |
LoseRARE / S&P RARE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RARE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -12.35% | 20.78% |
| Annualized return | -12.35% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RARE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.65% | 83.14% |
| Annualized return | -23.41% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | RARE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -60.38% | 319.30% |
| Annualized return | -8.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |